

22 July 2026

Emyria to Present at upcoming “Addressing the Mental Health Crisis” Event

Hosted by Impact Investment Summit and Novar Impact Capital, this Event brings together leaders in the mental health sector to discuss latest treatment innovations.

- **Emyria invited to present.** Executive Chair Greg Hutchinson has been invited to present at the upcoming “Addressing the Mental Health Crisis” event hosted by Impact Investment Summit and Novar Impact Capital¹ in Sydney in August.
- **Recognition of industry leadership.** The invitation reflects Emyria’s growing profile as a leader in evidence-based, intensive mental healthcare.
- **Sharing real-world expertise.** Emyria will participate in discussions on innovative mental healthcare delivery, preventative care, digital mental health solutions and emerging treatment pathways.
- **Highlighting the potential of psychedelic-assisted therapies.** Panel discussion will consider the role of psychedelic-assisted therapies in evidence-based mental healthcare and the potential to address unmet patient needs.

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in delivering evidence-based intensive mental-health care, is pleased to announce that Executive Chair, Greg Hutchinson has been invited to present at an upcoming industry event hosted by Impact Investment Summit and Novar Impact Capital.

The Event, entitled “Addressing the Mental Health Crisis”, will bring together leaders from the mental health sector to discuss innovative approaches to expanding access to evidence-based mental health treatments. Discussions will cover emerging models of care, preventative mental health initiatives and the potential of psychedelic-assisted therapies in addressing unmet mental health needs.

Executive Chair Greg Hutchinson will participate on a panel that will explore differing approaches to mental healthcare delivery, including preventative programs, digital mental health solutions, and new treatment pathways.

Event Details:

Date: Thursday 6 August 2026

Location: Esther Lane, Surry Hills, Sydney

Time: 5:30PM – 8PM AEST

Executive Chair Greg Hutchinson commented:

"Mental health remains one of the most significant healthcare challenges facing Australia and addressing this challenge will require a broad range of evidence-based approaches. We are pleased to contribute to this important discussion alongside other sector leaders and share our experience in delivering intensive mental health care, including innovative treatment pathways that have the potential to improve patient outcomes and expand access to care."

For more information, and to register for the event: <https://events.humanitix.com/addressing-the-mental-health-crisis>

This release has been approved by the Board of Emyria.

For further information, investment opportunities, or more about Emyria's approach to mental health treatment, please contact:

Greg Hutchinson

Executive Chair

1300 153 355 | investors@emyria.com

References:

1. <https://events.humanitix.com/addressing-the-mental-health-crisis>

For personal use only



Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development:

generates

informs

Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression.

Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

EMYRIA'S INTERACTIVE INVESTOR HUB

Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.